Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04256759 · ClinicalTrials.gov registry record · Phase 2
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT04256759: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT04256759 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04256759, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
To investigate the potential efficacy of dupilumab in the treatment of moderate to severe chronic hepatic pruritus.
Primary Outcome
Pruritus severity is measured using the peak PNRS assessed as a single, self-completed item that assesses the intensity of peak (worst) pruritus during the past 24 hours using the query: "On a scale of 0 to 10, with 0 being 'no itch 'and 10 being 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Measured before and after treatment. Scores range from 0 to 10 with higher scores indicating a worse outcome.
Interventions
- DRUG Dupilumab 300Mg Solution for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2024-09-06 |
| Phase | Phase 2 |
What the finished NCT04256759 record still lists
NCT04256759 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Dupilumab 300Mg Solution for Injection is the first listed.
NCT04256759 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04256759 about?
NCT04256759 is a clinical study titled "Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus". To investigate the potential efficacy of dupilumab in the treatment of moderate to severe chronic hepatic pruritus.
What is the current status of trial NCT04256759?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-09-01. Estimated completion is 2024-09-06.
What interventions are being tested in trial NCT04256759?
The interventions under investigation include: Dupilumab 300Mg Solution for Injection (DRUG).
Who is sponsoring clinical trial NCT04256759?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04256759's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI